{"groups":[{"description":"IL-15 for 10 doses over two weeks\n\nIL-15 plus: Recombinant Human IL-15 (subcutaneous (s.c.) rhIL-15) by s.c. injection Monday-Friday over two weeks.","id":"FG000","title":"Level 1 - 0.5 mcg/kg/Dose of Interleukin 15 (IL-15)"},{"description":"IL-15 for 10 doses over two weeks followed by alemtuzumab for 4 weeks\n\nIL-15 plus: Recombinant Human IL-15 (subcutaneous (s.c.) rhIL-15) by s.c. injection Monday-Friday over two weeks.\n\nalemtuzumab: Alemtuzumab three times a week for a total of 4 weeks of alemtuzumab treatment.","id":"FG001","title":"Level 2 - 1 mcg/kg/Dose of Interleukin-15 (IL-15) Followed by Alemtuzumab"},{"description":"IL-15 for 10 doses over two weeks followed by alemtuzumab for 4 weeks\n\nIL-15 plus: Recombinant Human IL-15 (subcutaneous (s.c.) rhIL-15) by s.c. injection Monday-Friday over two weeks.\n\nalemtuzumab: Alemtuzumab three times a week for a total of 4 weeks of alemtuzumab treatment.","id":"FG002","title":"Level 3 - 2 mcg/kg/Dose of Interleukin 15 (IL-15) Followed by Alemtuzumab"}],"periods":[{"dropWithdraws":[{"reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"1"},{"groupId":"FG002","numSubjects":"1"}],"type":"Progressive disease"}],"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"3"},{"groupId":"FG001","numSubjects":"4"},{"groupId":"FG002","numSubjects":"4"}],"type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"3"},{"groupId":"FG001","numSubjects":"3"},{"groupId":"FG002","numSubjects":"3"}],"type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"1"},{"groupId":"FG002","numSubjects":"1"}],"type":"NOT COMPLETED"}],"title":"Overall Study"}],"preAssignmentDetails":"No participants were enrolled on Level 3 - 3 mcg/kg/dose of Interleukin 15 (IL-15) Followed by Alemtuzumab."}